L&C BIO Co.,LTD (KOSDAQ:290650)
67,200
+600 (0.90%)
Dec 10, 2025, 3:30 PM KST
L&C BIO Co.,LTD Revenue
L&C BIO Co.,LTD had revenue of 22.56B KRW in the quarter ending September 30, 2025, with 21.66% growth. This brings the company's revenue in the last twelve months to 79.99B, up 19.41% year-over-year. In the year 2024, L&C BIO Co.,LTD had annual revenue of 72.09B with 9.35% growth.
Revenue (ttm)
79.99B
Revenue Growth
+19.41%
P/S Ratio
20.50
Revenue / Employee
567.32M
Employees
141
Market Cap
1.64T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72.09B | 6.17B | 9.35% |
| Dec 31, 2023 | 65.93B | 13.35B | 25.40% |
| Dec 31, 2022 | 52.57B | 6.90B | 15.10% |
| Dec 31, 2021 | 45.68B | 12.70B | 38.53% |
| Dec 31, 2020 | 32.97B | 3.82B | 13.11% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |